Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2011-04-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion
NCT02043964
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
NCT01723631
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
NCT05072691
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
NCT03624296
Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients
NCT01380041
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tears sampling
tears sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tears sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Progressive neurological deficit after 12 months
* At least 9 T2 brain lesions of minimum 3 mm evidenced by MRI and/or four or more T2 lesions of minimum 3 mm with positive Visual Evoked Potential and/or positive spinal cord MRI (at least two focal T2 lesions)
Exclusion Criteria
* recurrent forms of the disease
* Persons wearing contact lenses
* Ocular Infection
* Corticoid treatment at least 30 days before sampling
* immunosuppressive or immunomodulatory treatment 3 months before sampling
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Lille Catholic University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick Hautecoeur, MD
Role: PRINCIPAL_INVESTIGATOR
Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
Elisabeth Baumelou, MD
Role: STUDY_CHAIR
Groupement des Hôpitaux de l'Institut Catholique de Lille
Patrick Vermersch, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Régional, Universitaire de Lille
Christine Lebrun-Frenay, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nice
Jérome De Sèze, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Régional Universitaire de Strasbourg
Thibaut Moreau, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire Dijon
Pierre Clavelou, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Régional Universitaire de Clermont-Ferrand
Olivier Heinzlef, MD
Role: PRINCIPAL_INVESTIGATOR
Centre hospitalier intercommunal de Poissy
Christian Confavreux, MD
Role: PRINCIPAL_INVESTIGATOR
Hospices Civils de Lyon
Marc Debouverie, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Central Hospital, Nancy, France
Jean Pelletier, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
L'assistance Publique des Hôpitaux de Marseille
Bruno Brochet, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Bordeaux
Gilles Defer, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Caen
Eric Thouvenot, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nîmes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre hospitalier universitaire (CHU), Nice
Nice, Alpes Maritimes, France
Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
Lille, Nord, France
Centre hospitaliere universitaire
Bordeaux, , France
Centre hospitalier universitaire
Caen, , France
Centre hospitalier régional universitaire
Clermont-Ferrand, , France
Centre hospitalier universitaire
Dijon, , France
Centre hospitalier régional universitaire
Lille, , France
Hospices civils de Lyon
Lyon, , France
Assistance Publique - Hôpitaux de Marseille
Marseille, , France
Centre hospitalier universitaire
Nancy, , France
Centre hospitalier universitaire
Nîmes, , France
Centre hospitalier intercommunal
Poissy, , France
Centre hospitalier régional universtaire
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC-P0006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.